Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia
Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.Peer-Reviewed Original ResearchLost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Stahl M, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion On Investigational Drugs 2016, 25: 307-317. PMID: 26807602, DOI: 10.1517/13543784.2016.1146251.BooksConceptsHistone deacetylase inhibitorsAcute myeloid leukemiaMyeloid malignanciesMyelodysplastic syndromeMyeloid leukemiaDeacetylase inhibitorsSelection of patientsFuture clinical developmentClinical resultsDNA methyltransferase inhibitorClinical developmentSingle agentHDAC inhibitorsRobust biomarkersPleiotropic activitiesMalignancyPotential targetCancer therapyMethyltransferase inhibitorSyndromeLeukemiaInhibitorsEpigenetic modifiersEpigenetic changesMyeloma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply